摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-4-甲氧基苄胺 | 115514-77-7

中文名称
3-氯-4-甲氧基苄胺
中文别名
——
英文名称
(3-chloro-4-methoxyphenyl)methanamine
英文别名
3-chloro-4-methoxy-benzylamine;3-Chloro-4-methoxybenzenemethanamine
3-氯-4-甲氧基苄胺化学式
CAS
115514-77-7
化学式
C8H10ClNO
mdl
MFCD00995395
分子量
171.626
InChiKey
OCNMSDZALRAYEX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    110 °C(Press: 0.3 Torr)
  • 密度:
    1.180±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于氯仿(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2922299090
  • 包装等级:
    III
  • 危险类别:
    8
  • 危险性防范说明:
    P280,P301+P330+P331,P302+P352,P304+P340,P305+P351+P338,P310
  • 危险品运输编号:
    2735
  • 危险性描述:
    H314
  • 储存条件:
    室温且干燥环境中保存。

SDS

SDS:c06f0c51ec0b2ea5485e1c9eb8461660
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Chloro-4-methoxybenzylamine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-4-methoxybenzylamine
CAS number: 115514-77-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10ClNO
Molecular weight: 171.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氯-4-甲氧基苄胺三乙胺间氯过氧苯甲酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下, 以 四氢呋喃乙醇乙酸乙酯N,N-二甲基甲酰胺 为溶剂, 反应 0.67h, 生成 阿伐那非
    参考文献:
    名称:
    一种用于制备阿伐那非的中间体及其制备方 法
    摘要:
    本发明提供了一种新的中间体Ⅳ,用于制备阿伐那非,该中间体具有如下通式Ⅳ:式中R代表以下基团:C1‑C20的烷基亚磺酰基、C1‑C20的烷基磺酰基。该中间体纯度高、适合工业化生产,可经过一步化学反应得到阿伐那非。本发明同时提供了该中间体的制备方法,及利用该中间体制备阿伐那非的方法。
    公开号:
    CN104059025B
  • 作为产物:
    描述:
    3-氯-4-甲氧基苄醇盐酸氯化亚砜 作用下, 以 乙醇二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 3.0h, 生成 3-氯-4-甲氧基苄胺
    参考文献:
    名称:
    一种阿伐那非重要中间体的制备方法
    摘要:
    本发明提供一种阿伐那非重要中间体的制备方法,采用以下路线制得目标化合物(3-氯-4-甲氧基苄胺):。本发明原料价廉易得,工艺路线短,反应条件温和,设备要求低,对操作人员的健康危害小,符合绿色化学理念。本发明收率高,产品纯度高,适合工业化生产。
    公开号:
    CN105646240A
  • 作为试剂:
    描述:
    4-氯-2-甲硫基嘧啶-5-羧酸乙酯3-氯-4-甲氧基苄胺 、 、 、 柠檬酸3-氯-4-甲氧基苄胺 ice 、 乙酸乙酯柠檬酸 、 Brine 、 Sodium sulfate-III正己烷 作用下, 以 N,N-二甲基甲酰胺三乙胺 为溶剂, 反应 0.83h, 以to give 4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonyl-2-methylthiopyrimidine (38.34 g), m.p. 86° C.的产率得到阿伐那非中间体
    参考文献:
    名称:
    Aromatic nitrogen-containing 6-membered cyclic compounds
    摘要:
    一种含芳香基和氮的6元环化合物,化学式为(I):其中环A是取代或未取代的含氮杂环基团;R1是取代或未取代的低碳基基团,-NH-Q-R3(其中R3是取代或未取代的含氮杂环基团,Q是低碳亚基基团或单键),或-NH-R4(其中R4是取代或未取代的环烷基基团);R2是取代或未取代的芳基基团;Y和Z中的一个是═CH—,另一个是═N—,或其药学上可接受的盐。这些化合物表现出优异的选择性PDE V抑制活性,因此在预防或治疗阴茎勃起功能障碍等方面具有用途。
    公开号:
    US06656935B2
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF<br/>[FR] NOUVEAUX INHIBITEURS DE LA PHOSPHODIESTÉRASE ET UTILISATIONS DE CEUX-CI
    申请人:UNIV COLUMBIA
    公开号:WO2013109738A1
    公开(公告)日:2013-07-25
    The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.
    该发明提供了新型苯并萘啉衍生物和包含新型苯并萘啉衍生物的组合物。在某些实施例中,这些化合物是磷酸二酯酶抑制剂。该发明还提供了一种抑制磷酸二酯酶的方法,包括将磷酸二酯酶与新型苯并萘啉衍生物或包含新型苯并萘啉衍生物的组合物接触。该发明还提供了一种治疗神经退行性疾病、增强记忆或长时程增强的方法,使用新型苯并萘啉衍生物或包含新型苯并萘啉衍生物的组合物。在某些实施例中,磷酸二酯酶是PDE5。
  • Phosphodiesterase inhibitors and uses thereof
    申请人:THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    公开号:US10626113B2
    公开(公告)日:2020-04-21
    The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.
    这项发明提供了新型苯并萘啶衍生物和包含新型苯并萘啶衍生物的组合物。在某些实施例中,这些化合物是磷酸二酯酶抑制剂。该发明还提供了一种通过将磷酸二酯酶与新型苯并萘啶衍生物或包含新型苯并萘啶衍生物的组合物接触来抑制磷酸二酯酶的方法。该发明还提供了一种治疗神经退行性疾病、增强记忆或长时程增强的方法,该方法使用新型苯并萘啶衍生物或包含新型苯并萘啶衍生物的组合物。在某些实施例中,磷酸二酯酶是PDE5。
  • Nickel-Catalyzed Enantioselective α-Alkenylation of <i>N</i>-Sulfonyl Amines: Modular Access to Chiral α-Branched Amines
    作者:Lun Li、Yu-Cheng Liu、Hang Shi
    DOI:10.1021/jacs.1c00622
    日期:2021.3.24
    α-branched amines are common structural motifs in functional materials, pharmaceuticals, and chiral catalysts. Therefore, developing efficient methods for preparing compounds with these privileged scaffolds is an important endeavor in synthetic chemistry. Herein, we describe an atom-economical, modular method for a nickel-catalyzed enantioselective α-alkenylation of readily available linear N-sulfonyl amines
    手性α-支化胺是功能材料、药物和手性催化剂中常见的结构基序。因此,开发用于制备具有这些特权支架的化合物的有效方法是合成化学中的一项重要努力。在这里,我们描述了一种原子经济的模块化方法,用于镍催化的线性N 的对映选择性 α-烯基化-磺胺与炔烃可提供多种烯丙基胺,无需外源性氧化剂、还原剂或活化剂。该方法为构建手性α-支化胺以及α-氨基酰胺和β-氨基醇等衍生物提供了一个平台,这些衍生物可以方便地从新引入的烯烃中获得。鉴于该方法的通用性、多功能性和高原子经济性,我们预计它将具有广泛的合成效用。
  • Anti-ischemic 2,4-diaminoquinazolines
    申请人:Eisai Co., Ltd.
    公开号:US05576322A1
    公开(公告)日:1996-11-19
    The invention is directed to certain 2,4-diaminoquinazoline compounds, their pharmaceutically acceptable salts, the pharmaceutical compositions comprising those compounds and their therapeutic methods of use. The compounds possess anti-ischemic activity.
    这项发明涉及特定的2,4-二氨基喹唑啉化合物,它们的药用盐,包含这些化合物的药物组合物以及它们的治疗用途方法。这些化合物具有抗缺血活性。
  • Prodrugs Of Bicyclic Substituted Pyrimidine Type PDE-5 Inhibitors
    申请人:XUANZHU PHARMA CO., LTD.
    公开号:US20160046654A1
    公开(公告)日:2016-02-18
    Provided are prodrugs of a bicyclic substituted pyrimidine type PDE-5 inhibitors, pharmaceutically acceptable salts or stereoisomers thereof. Also provided are methods for preparing these prodrug compounds, pharmaceutical preparations, and pharmaceutical compositions, as well as a use of these compounds, pharmaceutical preparations and pharmaceutical compositions in the manufacture of medicaments for treatment and/or prophylaxis of sexual dysfunction and lower urinary tract symptoms.
    提供了一种双环替代嘧啶型PDE-5抑制剂的前药,其药用盐或立体异构体。还提供了制备这些前药化合物、制药制剂和制药组合物的方法,以及这些化合物、制药制剂和制药组合物在制造用于治疗和/或预防性功能障碍和下尿路症状的药物中的用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐